AI summary · may contain errors
A single infusion of amrecibart or cenvacibart reduced adjudicated venous thromboembolism by day 14 after PICC placement, with 20% vs 43% on placebo.
Elsevier BV · Clinical Medicine · ISSN 2352-3026
Rebuilt
Newest first · last 60 days
AI summary · may contain errors
A single infusion of amrecibart or cenvacibart reduced adjudicated venous thromboembolism by day 14 after PICC placement, with 20% vs 43% on placebo.
AI summary · may contain errors
Hereditary haemorrhagic telangiectasia remains without licensed therapies worldwide, despite a high global burden and rapid development of multiple investigational vascular and haemostatic agents.
AI summary · may contain errors
In an international retrospective cohort of 1174 biopsy-proven Erdheim-Chester disease patients, 261 (22%) died after a median 49 months, with older age and treatment non-response linked to higher mortality.
AI summary · may contain errors
Adding decitabine to busulfan-cyclophosphamide conditioning before allogeneic HSCT reduces 2-year relapse incidence in adults with KMT2A-rearranged leukaemia from 29% to 12%.
Journals this month
Topics moving, week to 17 Nov 2026
By field